Risk of all-cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network.

ABSTRACT:

Background

Limited data are available on the risk of pancreatic adverse events among people with obesity or type 2 diabetes mellitus (T2DM) initiating glucagon-like peptide-1 receptor agonist (GLP-1 RA).

Methods

Retrospective study utilizing data from a federated research network (TriNetX). Adult people (≥ 18 years) with a diagnosis of obesity (body mass index ≥ 30 kg/m²) or T2DM (ICD-10-CM: E11) between 2018 and 2024 were subdivided in two mutually exclusive cohorts: (1) GLP-1 RA Users; and (2) Non-GLP-1 RA Users. Primary outcomes were 1-year risk of all-cause death and a composite outcome (acute pancreatitis, chronic pancreatitis). Secondary outcomes included the individual components of the composite outcome and pancreatic cancer. Cox regression analyses were e

SUBMITTER: Tartaglia E 

PROVIDER: S-EPMC12628983 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature